Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2

Conditions

Breast Neoplasms 1129Carcinoma, Non-Small-Cell Lung 718Neoplasms 546Prostatic Neoplasms 505Colorectal Neoplasms 439Multiple Myeloma 338Lung Neoplasms 310Neoplasm Metastasis 289Leukemia, Myeloid, Acute 263Stomach Neoplasms 248Carcinoma, Hepatocellular 246Ovarian Neoplasms 225Rectal Neoplasms 211Colonic Neoplasms 204Lymphoma, Follicular 200Lymphoma 199Leukemia 190Uterine Cervical Neoplasms 181Head and Neck Neoplasms 174Pancreatic Neoplasms 172Lymphoma, Non-Hodgkin 167Leukemia, Lymphocytic, Chronic, B-Cell 166Lymphoma, Large B-Cell, Diffuse 163Recurrence 162Melanoma 158Precursor Cell Lymphoblastic Leukemia-Lymphoma 154Squamous Cell Carcinoma of Head and Neck 147Pain 141Urinary Bladder Neoplasms 139Brain Neoplasms 133

Interventions

Receptor-Like Protein Tyrosine Phosphatases, Class 2 1Octreotide 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Interventional × Malignant Carcinoid Syndrome × Clear all
NCT00092287 2020-04-30

Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome

Ipsen

Phase 3 Terminated
4 enrolled
Endocrine

Malignant Carcinoid Syndrome, Serotonin Syndrome

NCT00412061 2014-11-21

RADIANT-2

Novartis

Phase 3 Completed
429 enrolled 13 charts
Endocrine

Carcinoid Tumor, Carcinoma, Malignant Carcinoid Syndrome, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡